Shockwave™ Vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes

Last updated: February 11, 2025
Sponsor: Baylor Research Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Shockwave Catheter

CFA Endarterectomy

Clinical Study ID

NCT06829914
021-263
  • Ages > 18
  • All Genders

Study Summary

The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. The study will challenge the current guideline that recommends common femoral endarterectomy (CFE) as the primary treatment for symptomatic CFA stenosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab):

  1. CFA atherosclerotic stenosis 60-100%

  2. Moderate to severe calcification reported on imaging

  3. Lifestyle-limiting intermittent claudication (IC) or chronic limb-threateningischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5

  4. Failing conservative therapy

  5. Operative candidate for CFE prior to enrollment

  6. ≥18 years of age

Exclusion

Exclusion Criteria:

A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:

  1. History of CFE or bypass in affected limb

  2. Thrombosis of affected CFA

  3. Aneurysm in the common femoral artery of target limb

  4. Known target lesion restenosis (re-narrowing of the artery to ≥50% following thealleviation of a previous narrowing within 3 months)

  5. Any preceding percutaneous cardiovascular intervention within 2 weeks

  6. Inability to tolerate DAPT

  7. Known coagulopathy or bleeding diathesis, thrombocytopenia with platelet count <100,000/µL

  8. Uncontrolled diabetes (HbA1c ≥10.0%)

  9. Non-ambulatory

  10. Extensive tissue loss requiring amputation or salvageable only with complex footreconstruction or non-traditional transmetatarsal amputations

  11. MI within 6 weeks (defined as presumed ischemic symptoms (chest pain, ST-segmentdeviation and troponin higher than 2 times the upper limit of normal))

  12. Stroke within 3 months (defined as sudden transient or irreversible focalneurological deficit resulting from a cerebrovascular cause)

  13. Pregnant

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Shockwave Catheter
Phase:
Study Start date:
March 07, 2024
Estimated Completion Date:
March 30, 2026

Study Description

This is a pilot, prospective, randomized clinical trial. This trial compares patients with severe symptomatic moderate to severe calcified CFA stenosis undergoing traditional gold standard CFA endarterectomy to innovative technique of endovascular treatment using Shockwave™ Intra vascular Lithotripsy (IVL) using M5+ balloon with Drug coated balloon to achieve removal and debulking of plaque and achieve luminal gain. Patients who meet inclusion criteria will be informed and consented by a clinical coordinator if they wish to participate in the trial. If participants are candidates for surgery, they will then be randomized into one of two cohorts, receiving either Shockwave™ IVL + DCB (drug-coated balloon) procedure or a standard surgical endarterectomy. The study compares the 1-year efficacy and 6-month safety outcomes post-procedure for patients with severe, symptomatic CFA stenosis receiving Shockwave™ IVL with DCB versus surgical endarterectomy.

Connect with a study center

  • Baylor Scott & White The Heart Hospital - Plano

    Plano, Texas 75093
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.